MLL5, a histone modifying enzyme, regulates androgen receptor activity in prostate cancer cells by recruiting co-regulators, HCF1 and SET1
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
In prostate cancer, the androgen receptor (AR) transcription factor is a major regulator of cell proliferation and metastasis. To identify new AR regulators, we focused on Mixed lineage leukemia 5 (MLL5), a histone-regulating enzyme, because significantly higher MLL5 expression was detected in prostate cancer tissues than in matching normal tissues. When we expressed shRNAs targeting MLL5 gene in prostate cancer cell line, the growth rate and AR activity were reduced compared to those in control cells, and migration ability of the knockdown cells was reduced significantly. To determine the molecular mechanisms of MLL5 on AR activity, we proved that AR physically interacted with MLL5 and other co-factors, including SET-1 and HCF-1, using an immunoprecipitation method. The chromatin immunoprecipitation analysis showed reduced binding of MLL5, co-factors, and AR enzymes to AR target gene promoters in MLL5 shRNA-expressing cells. Histone H3K4 methylation on the AR target gene promoters was reduced, and H3K9 methylation at the same site was increased in MLL5 knockdown cells. Finally, xenograft tumor formation revealed that reduction of MLL5 in prostate cancer cells retarded tumor growth. Our results thus demonstrate the important role of MLL5 as a new epigenetic regulator of AR in prostate cancer.
Abstract
In prostate cancer, the androgen receptor (AR) transcription factor is a major regulator of cell proliferation and metastasis. To identify new AR regulators, we focused on Mixed lineage leukemia 5 (MLL5), a histone-regulating enzyme, because significantly higher MLL5 expression was detected in prostate cancer tissues than in matching normal tissues. When we expressed shRNAs targeting MLL5 gene in prostate cancer cell line, the growth rate and AR activity were reduced compared to those in control cells, and migration ability of the knockdown cells was reduced significantly. To determine the molecular mechanisms of MLL5 on AR activity, we proved that AR physically interacted with MLL5 and other co-factors, including SET-1 and HCF-1, using an immunoprecipitation method. The chromatin immunoprecipitation analysis showed reduced binding of MLL5, co-factors, and AR enzymes to AR target gene promoters in MLL5 shRNA-expressing cells. Histone H3K4 methylation on the AR target gene promoters was reduced, and H3K9 methylation at the same site was increased in MLL5 knockdown cells. Finally, xenograft tumor formation revealed that reduction of MLL5 in prostate cancer cells retarded tumor growth. Our results thus demonstrate the important role of MLL5 as a new epigenetic regulator of AR in prostate cancer.
참고문헌 (31)
- Siegel RL, "Cancer statistics, 2019", CA : A Cancer Journal for Clinicians, 69, pp.7~34 (2019)
- Masson S, "Metastatic castrate-resistant prostate cancer : dawn of a new age of management", BJU Int, 110, pp.1110~1114 (2012)
- Claessens F, "Emerging mechanisms of enzalutamide resistance in prostate cancer", Nat Rev Urol, 11, pp.712~716 (2014)
- Cucchiara V, "Epigenomic regulation of androgen receptor signaling : potential role in prostate cancer therapy", Cancers, 9, pp.9~ (2017)
- Peterson CL, "Histones and histone modifications", Curr Biol, 14, pp.R546~551 (2004)
- Gaughan L, "Regulation of the androgen receptor by SET9-mediated methylation", Nucleic Acids Res, 39, pp.1266~1279 (2011)
- Kang HB, "The histone methyltransferase, NSD2, enhances androgen receptor-mediated transcription", FEBS Lett, 583, pp.1880~1886 (2009)
- Varambally S, "The polycomb group protein EZH2 is involved in progression of prostate cancer", Nature, 419, pp.624~629 (2002)
- Cai C, "Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysinespecific demethylase 1", Cancer Cell, 20, pp.457~471 (2011)
- Metzger E, "LSD1demethylates repressive histone marks to promote androgenreceptor-dependent transcription", Nature, 437, pp.436~439 (2005)
- Kang MK, "Epigenetic gene regulation by histone demethylases : emerging role in oncogenesis and inflammation", Oral Dis, 23, pp.709~720 (2017)
- Willmann D, "Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor", Int J Cancer, 131, pp.2704~2709 (2012)
- Lee KH, "Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer", Int J Cancer, 143, pp.2849~2861 (2018)
- Zhou P, "MLL5 suppresses antiviral innate immune response by facilitating STUB1-mediated RIG-I degradation", Nat Commun, 9, pp.1243~ (2018)
- Deng LW, "MLL 5 protein forms intranuclear foci, and overexpression inhibits cell cycle progression", Proc Natl Acad Sci U S A, 101, pp.757~762 (2004)
- Ali M, "Molecular basis for chromatin binding and regulation of MLL5", Proc Natl Acad Sci U S A, 110, pp.11296~11301 (2013)
- Zhang Y, "MLL5 contributes to hematopoietic stem cell fitness and homeostasis", Blood, 113, pp.1455~1463 (2009)
- Yap DB, "Mll5 is required for normal spermatogenesis", PLoS One, 6, pp.e27127~ (2011)
- Mas YMS, "The human mixed lineage leukemia 5(MLL5), a sequentially and structurally divergent SET domain-containing protein with no intrinsic catalytic activity", PLoS One, 11, pp.e0165139~ (2016)
- Zhou P, "Mixed lineage leukemia 5(MLL5)protein regulates cell cycle progression and E2F1-responsive gene expression via association with host cell factor-1(HCF-1)", J Biol Chem, 288, pp.17532~17543 (2013)
- Wysocka J, "Human Sin3 deacetylase and trithoraxrelated Set1", Ash2 histone H3-K4 methyltransferase are tethered together selectively by the cell-proliferation factor HCF-1, 2003, pp.17, 896~911
- Mora GR, "Autoregulation of the androgen receptor at the translational level : Testosterone induces accumulation of androgen receptor mrna in the rat ventral prostate polyribosomes", Steroids, 64, pp.587~591 (1999)
- Coutinho I, "Androgen receptor signaling in castration-resistant prostate cancer : a lesson in persistence", Endocr Relat Cancer, 23, pp.T179~T197 (2016)
- Lu S, "Regulation of androgendependent prostatic cancer cell growth : androgen regulation of CDK2, CDK4, and CKI p16 genes", Cancer Res, 57, pp.4511~4516 (1997)
- Liao X, "Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer", Endocrinology, 144, pp.1656~1663 (2003)
- 김은영, "6-sialyllactose ameliorates dihydrotestosterone-induced benign prostatic hyperplasia through suppressing VEGF-mediated angiogenesis", BMB Reports, 52(9), pp.560~565 (2019), 생화학분자생물학회[DOI]
- Linder S, "Enzalutamide therapy for advanced prostate cancer : efficacy, resistance and beyond", Endocr Relat Cancer, 26, pp.R31~R52 (2018)
- Altintas DM, "Direct cooperation between androgen receptor and E2F1 reveals a common regulation mechanism for androgen-responsive genes in prostate cells", Mol Endocrinol, 26, pp.1531~1541 (2012)
- Sharma A, "The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression", J Clin Invest, 120, pp.4478~4492 (2010)
- Narayanan A, "The coactivator host cell factor-1 mediates Set1 and MLL1H3K4 trimethylation at herpesvirus immediate early promoters for initiation of infection", Proc Natl Acad Sci U S A, 104, pp.10835~10840 (2007)
- Schrecengost R, "Molecular pathogenesis and progression of prostate cancer", Semin Oncol, 40, pp.244~258 (2013)